Tagomics launches LiquiPath, a cell-free DNA test for multi-organ drug safety monitoring
Cambridge, UK-based precision medicine company Tagomics Ltd has launched LiquiPath™, a cross-species, multi-organ “liquid pathology” platform designed for non-invasive monitoring of drug-related toxicity. The platform is intended for use across preclinical studies, clinical development and on-market surveillance, with an early access programme now open to drug developers.
Addressing limitations of conventional toxicity monitoring
Therapy-induced toxicity remains a significant contributor to trial failures, programme delays and treatment interruptions, and can result in irreversible organ damage. Conventional safety monitoring approaches, which rely on non-specific biomarkers, imaging and clinical symptoms, often identify injury only after substantial damage has already occurred.
LiquiPath combines Tagomics’ epigenetic technology, Activace, with proprietary cell-type-specific methylation atlases and deconvolution algorithms to trace circulating cell-free DNA (cfDNA) back to its tissue of origin. The platform is designed to enable sensitive, multi-tissue detection of treatment-related adverse effects from a single blood sample.
Applications across preclinical and clinical settings
In preclinical research, the platform’s multi-species, organ-agnostic capabilities are intended to reduce reliance on histopathology and animal use, while supporting faster decision-making and toxicity-risk stratification. In clinical settings, LiquiPath is designed to enable earlier detection of subclinical toxicity, support adverse event prediction and improve patient stratification, with the aim of helping patients benefit from therapies for longer.
Pharmaceutical collaborations under way
LiquiPath is being developed through projects with several leading pharmaceutical partners, including AstraZeneca, spanning multiple therapeutic modalities and stages of development. Tagomics is now inviting additional partners to join its early access programme and collaborate on priority use cases, validation studies and future platform capabilities.
Dr Jack Kennefick, CEO and co-founder of Tagomics, commented: “Drug safety monitoring has remained largely unchanged for decades, with many current tools detecting damage only after it has occurred. LiquiPath is designed to bring drug safety monitoring into the era of precision medicine, aiming to transform how toxicity is detected and understood across the drug development lifecycle. By reading tissue-specific cell-free DNA signals in blood, we believe the platform can help drug developers detect toxicity earlier and understand where injury is occurring. These insights are intended to support faster and better-informed decisions and help patients derive greater benefit from cutting-edge therapies.”
He added that the launch, reflected in the company’s new branding and website, marks an expansion of Tagomics’ capabilities beyond cancer detection, furthering its mission of transforming precision medicine.
For more information, visit: https://tagomics.com/organ-health
Digital issue: Please click here for more information
Dr Jack Kennefick, CEO and co-founder of Tagomics
